Linked guidances/guidelines are in English, unless stated otherwise. Language codes are given according to ISO 639-1 (i.e., English en, French fr, German de, Spanish es, Danish da, Portuguese pt, Japanese ja, Chinese zh, Russian ru, Arabic ar, …)
Although links to documents are considered current with 19 Oct 2022, you should always consult websites of the respective regulatory body for any updated versions. Documents superseded by newer versions are striken through. While obsolete, previous versions are helpful in dealing with deficiency letters issued for “old” studies. Documents published within the last two years are marked. Note also updates/revisionsUD and additionsnew within the last six months.
If you encounter broken links or are acquainted with any missing / updated documents please notify the webmaster.
- International Council for Harmonisation
- Quality
- Validation of Analytical Procedures: Text and Methodology Q2(R1): step 4, Nov 2005 (PDF180KiB)
- Analytical Procedure Development and Revision of Q2(R1): Concept Paper Nov 2018 (PDF92KiB)
- Specifications: Test Procedures and Acceptance Criteria
- New Drug Substances and New Drug Products: Chemical Substances Q6A: Oct 1999 (PDF211KiB, Decision Trees PDF46KiB)
- Biotechnological/Biological Products Q6B: Mar 1999 (PDF204KiB)
- Pharmaceutical Development Q8(R2): step 4, Aug 2009 (PDF764KiB)
- Safety
- Efficacy
- Development Safety Update Report E2F: step 4, Aug 2010 (PDF334KiB)
- Structure and Content of Clinical Study Reports E3: Nov 1995 (PDF471KiB), Q&As (R1): Jul 2012 (PDF158KiB)
- Good Clinical Practice E6(R1): step 4, Jun 1996 ( PDF380KiB; including IB template)
- Integrated Addendum to ICH E6(R1) E6(R2): Nov 2016 (PDF456KiB)
- General Considerations for Clinical Trials E8(R1): step 2 May 2019 (PDF295KiB)
- General Considerations for Clinical Trials E8: Jul 1997 (PDF182KiB)
- Ethnic Factors in the Acceptability of Foreign Clinical Data E5(R1): step 4, Mar 1998 (PDF187KiB), Q&A: Jun 2006 (PDF66KiB)
- Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A: step 4, Oct 1994 (PDF145KiB)
- Statistical Principles for Clinical Trials E9: Feb 1998 (PDF284KiB)
- Addendum: Statistical Principles for Clinical Trials E9(R1): step 2, Jun 2017 (PDF310KiB), Concept Paper Oct 2014 (PDF173KiB)
- Multidisciplinary
- BCS-based Biowaivers M9: step 4, Nov 2019 (PDF222KiB), Q&A: Nov 2019 (PDF176KiB), step 2, Jun 2018 (PDF183KiB)
- Bioanalytical Method Validation M10: step 2, Feb 2019 (PDF367KiB)
- Drug Interaction Studies M12: step 1, Nov 2019 (PDF86KiB)
- BE for IR Solid Oral Dosage Forms M13: step 1, Jul 2020 (PDF640KiB)
- World Health Organization
- GL for GCP for trials on pharmaceutical products (WHO TRS No. 850, Annex 3): 1995 (PDF104KiB)
- Handbook for GCP: 2005 (PDF560KiB)
- Prequalification Programme
Medicines / FPPs
- Main text: GL on Generics – Pharmaceutical Quality and BE (333KB PDF); selected annex and supplement below.
- Advice on the design of BE studies: 2009 (HTML)
- Annex 7, Presentation of BE Trial Information (BTIF): Jan 2010 (DOC440KiB, ZIP/DOC245KiB),
Aug 2005 (DOC424KiB, ZIP/DOC244KiB)
- Supplement 1 (Dissolution testing): Jul 2005 (PDF103KiB)
- Procedure for prequalification of pharmaceutical products: 2011 (PDF120KiB)
- GL on the requalification of prequalified dossiers: 2010 (PDF66KiB)
- GL for the preparation of a CRO master file: 2010 (PDF51KiB)
- Frequent deficiencies in BE study protocols:new Nov 2020 (PDF215KiB)
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fifty-first Report (WHO TRS No. 992), Annex 6, Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability: 2017 (PDF266KiB)
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fiftieth Report (WHO TRS No. 966), Annex 10, General guidance on variations to multisource pharmaceutical products: 2016 (PDF129KiB)
- Multisource (Generic) Products: Apr 2017 (PDF276KiB), Revised Draft for Comment, Jul 2014 (PDF1.55MiB),
Draft Rev. 2005 (PDF277KiB), Final 1998 ( PDF666KiB)
- GL on data integrity: Draft for Comment, Jun 2020 (PDF744KiB)
- Good Chromatography Practices: Draft for Comment, Feb 2019 (PDF340KiB)
- International Comparator Products
- International Comparator: Draft Rev., 2005 (PDF358KiB)
- Medicines for HIV/AIDS and related diseases: Feb 2012 (PDF56KiB)
- Influenza-specific antiviral medicines: Jun 2009 (PDF45KiB)
- Anti-malarial medicines: Feb 2012 (PDF67KiB)
- Anti-tuberculosis medicines: Feb 2012 (PDF29KiB)
- Reproductive Health Medicines: Jul 2014 (PDF29KiB), Recommended comparator products: Mar 2012 (PDF121KiB)
- Biowaivers
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fifty-fourth Report (WHO TRS No. 1025), Annex 12, WHO “Biowaiver List”: proposal to waive in vivo bioequivalence requirements for WHO Model List of
Essential Medicines immediate-release, solid oral dosage forms: 2020 (PDF113KiB)
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fifty-fourth Report (WHO TRS No. 1019), Annex 4, Protocol to conduct equilibrium solubility experiments for the purpose of biopharmaceutics classification system-based classification of active pharmaceutical ingredients for biowaiver: 2019 (PDF346KiB)
- General Notes on Biopharmaceutics Classification System (BCS)-based Biowaiver Applications:
Nov 2014 (PDF81KiB),
Final Nov 2011 ( PDF49KiB), Draft 2005 (PDF197KiB)
- Application Form: Dec 2008 (DOC62KiB)
- Additional Strength: May 2012 (DOC88KiB)
- Guidance for Organizations performing in vivo Bioequivalence Studies: (WHO TRS No. 966, Annex 9 PDF218KiB 2016, Draft 2005 PDF103KiB)
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-ninth Report (WHO TRS No. 929, Annex 5); Fixed dose combinations: Jun 2005 (PDF974KiB)
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Forty-sixth Report (WHO TRS No. 970), Annex 4, Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product for the WHO Prequalification of Medicines Programme: quality part: 2012 (PDF1.0MiB)
- WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report (WHO TRS No. 937): May 2006 (PDF1.9MiB); Annexes 7–9 are available in separate documents:
- Annex 7: Multisource (generic) pharmaceutical products: guidelines
on registration requirements to establish interchangeability (Forty-ninth Report, WHO TRS No. 992, May 2015
PDF280KiB), WHO TRS No. 937, May 2006 PDF425KiB
- Annex 8: Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms (PDF464KiB)
- Annex 9: Additional guidance for organizations performing in vivo bioequivalence studies (PDF371KiB)
- WHO Expert Committee on Biological Standardization; Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs): Oct 2009 (PDF256KiB)
- Handbook Good Laboratory Practice (GLP): 2001 (PDF1.1MiB)
- Training manual for the trainer: 2001 (PDF2.4MiB)
- Training manual for the trainee: 2001 (PDF2.3MiB)
- European Union (EMA)
EudraLex – EU Legislation
- Procedure for European Union Guidelines and Related Documents within the Pharmaceutical Legislative Framework: Jan 2009 (PDF102KiB)
- Guidelines: Clinical Efficacy and Safety HTML, Multidisciplinary HTML
- Legislation
- Directive 2001/20/EC (Implementation of GCP in the Conduct of Clinical Trials on Medicinal Products for Human Use): Apr 2001 (PDF152KiB)
- Directive 2003/94/EC (Principles and Guidelines of GMP in Respect of Medicinal Products for Human Use and Investigational Medicinal Products for Human Use): Oct 2003 (PDF115KiB)
- Directive 2004/9/EC (Inspection and Verification of GLP): Feb 2004 (in many European languages and formats [HTML, PDF, TIFF], e.g., PDF247KiB en)
- Directive 2004/10/EC (Harmonisation of Laws, Regulations and Administrative Provisions relating to the Application of the Principles of GLP and the Verification of their Applications for Tests on Chemical Substances): Feb 2004 (in many European languages and formats [HTML, PDF, TIFF], e.g., PDF239KiB en)
- Directive 2005/28/EC (Principles and detailed Guidelines for GCP as regards IMPs for Human Use, as well as the Requirements for Authorisation of the Manufacturing or Importation of such Products): Apr 2005 (PDF66KiB)
- Requirements to the Chemical and Pharmaceutical Quality Documentation concerning IMPs in Clinical Trials: Mar 2006 (PDF141KiB)
- Definition of IMPs and NIMPs: Jul 2006 (PDF51KiB)
- Additional Information on IMPs: Apr 2007 (PDF41KiB)
- Guidance on IMPs and ‘NIMPs’: Rev.1, March 2011 (PDF49KiB)
- GMP, Medicinal Products for Human and Veterinary Use, Annex 13, IMPs: Jan 2010 (PDF66B)
- Bioavailability / Bioequivalence
- Guidelines / Notes for Guidance and associated documents
- Bioequivalence: Jan 2010 (PDF236KiB), Overview of comments Jan 2010 (PDF1.5MiB)
Draft Jul 2008 (PDF436KiB) Recommendation on the Need for Revision of NfG on BA/BE: May 2007 (PDF38KiB)
- Appendix IV of the GL on the Investigation on
BE (CPMP/EWP/QWP/1401/98 Rev.1): Presentation of Biopharmaceutical and Bioanalytical Data in Module 2.7.1: Final Nov 2011 (PDF137KiB), Overview of Comments (PDF232KiB),
Draft Feb 2011 (PDF155KiB), CP Apr 2010 (PDF99KiB)
- RP on the dissolution specification for generic oral IR products: May 2016 (PDF146KiB)
- RP: Advice to Applicants/Sponsors/CROs of BE Studies: Sep 2008 (PDF104KiB)
- Q & A on the adequacy of the Mahalanobis distance to assess the comparability of drug dissolution profiles: Jul 2018 (PDF168KiB)
CP on BCS-based Biowaiver: May 2007 (PDF43KiB)
BA/BE for HVDs/HVDPs: Apr 2006; removed in Oct 2007 from the EMEA’s site (Deleted – This topic will be addressed in the revision of “NfG on the investigation of BA and BE” CHMP/EWP/200943/07) PDF36KiB
Q & A on the BA and BE GL: Jul 2006 ( PDF118KiB)
NfG on the Investigation of BA and BE: Jul 2001 (PDF99KiB),
Jun 1992 ( PDF64KiB)
- GL on the PK and clinical evaluation of MR dosage forms: Nov 2014 (PDF499KiB)
Draft Feb 2013 (PDF395KiB) CP May 2010 (PDF78KiB)
MR Oral / Transdermals: Jul 1999 (PDF122KiB)
- GL on quality of oral MR products: Mar 2014 (PDF188KiB), Overview of comments (PDF511KiB)
Draft Sep 2012 (oral MR products PDF187KiB CP Jul 2010 (PDF95KiB)
- GL on quality of transdermal patches: Oct 2014 (PDF242KiB)
Draft Sep 2012 (PDF241KiB), CP Jul 2010 (PDF95KiB)
- GL – therapeutic equivalence for locally applied and locally acting products in the GIT: Draft Mar 2017 (PDF318KiB),
CP Sep 2013 (PDF115KiB), NfG on the clinical requirements for locally applied and locally acting products containing known constituents: Jun 1996 (PDF39KiB)
- Product-specific bioequivalence guidance
- Abiraterone (Rev. 1 Feb 2021, Rev. 1 Draft May 2020, Final Feb 2017, Draft Aug 2016)
- Acenocoumarol (Final Apr 2021, Draft Oct 2020) NTID
- Agomelatine (Final Jul 2018, Draft Jan 2018)
- Alectinib (Final Sep 2019, Draft Jan 2019)
- Aliskiren (Final Dec 2018, Draft May 2018)
- Apixaban (Final Jul 2019, Draft May 2018)
- Asenapine (Final Apr 2016, Draft Jul 2015)
- Cabozantinib (Final Sep 2019, Draft Dec 2018)
- Capecitabine (Final May 2015, Draft Nov 2013)
- Carglumic acid (Final Apr 2015, Draft Nov 2013)
- Cholic acid (Final Jul 2018, Draft Jan 2018)
- Colchicine (Final Sep 2019, Draft Feb 2019) NTID
- Crizotinib (Final Jul 2017, Draft Dec 2016)
- Dabigatran (Final May 2018, Draft Dec 2016)
- Dasatinib (Rev. 1 Draft May 2020, Final Nov 2014, Draft Nov 2013)
- Deferasirox (Draft Dec 2020)
- Dimethyl fumarate (Final May 2018, Draft Jul 2017)
- Dolutegravir (Final Feb 2018, Draft Jul 2017)
- Dronedarone (Final Feb 2018, Draft Jul 2017)
- Elvitegravir (Final Jun 2017, Draft Dec 2016)
- Elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (Final Jun 2017, Draft Dec 2016)
- Emtricitabine / rilpivirine / tenofovir disoproxil (Final Jun 2017, Draft Dec 2016)
- Emtricitabine / tenofovir disproxil (Final Nov 2014, Draft Nov 2013)
- Entecavir (Final Apr 2016, Draft Oct 2015)
- Erlotinib (Final Nov 2014, Draft Nov 2013)
- Etonogestrel / ethinylestradiol (Draft Apr 2019)
- Everolimus (Final Jan 2017, Draft Apr 2016) NTID
- Exetanide (Final Mar 2017, Draft Aug 2016)
- Ezetimibe (Final Sep 2019, Draft Dec 2018)
- Fingolimod (Final Dec 2016, Draft Apr 2016)
- Gefitinib (Draft May 2018)
- Ibuprofen (Final May 2018, Draft Aug 2017)
- Imatinib (Final Apr 2015, Draft Nov 2013)
- Lapatinib (Draft 2 Jun 2020, Draft 1 May 2018)
- Ledipasvir / sofosbuvir (Final Jul 2018, Draft Jan 2018)
- Lenalidomide (Final Apr 2016, Draft Oct 2015)
- Levodopa / Carbidopa / Entacapone (Final Dec 2016, Draft Apr 2016)
- Levothyroxine (Draft May 2020) NTID
- Memantine (Final Apr 2015, Draft Nov 2013)
- Miglustat (Final Nov 2014, Draft Nov 2013)
- Octreotide acetate (Draft May 2018)
- Oseltamivir (Final Apr 2015, Draft Nov 2013)
- Palbociclib (Rev. 1 open for comments Nov 2020, Final Sep 2019, Draft Jan 2019)
- Paliperidone depot suspension (Final Feb 2017, Draft Aug 2016)
- Paliperidone PR tablets (Rev. 1 Final May 2018, Final Dec 2016, Draft Apr 2016)
- Paracetamol (Final Jan 2018, Draft Jul 2017)
- Pazopanib (Final Dec 2016, Draft Apr 2016)
- Pegylated liposomal doxorubicin (Final Dec 2018, Draft May 2018)
- Posaconazole suspension (Final Apr 2015, Draft Nov 2013)
- Posaconazole tablet (Final Jul 2018, Draft Jan 2018)
- Prasugrel (Rev. 1 May 2018, Draft Jul 2017; Final Apr 2016, Draft Jul 2015)
- Repaglinide (Final Nov 2014, Draft Nov 2013)
- Rilpivirine (Final Jan 2018, Draft Jul 2017)
- Rivaroxaban (Final Apr 2016, Draft Oct 2015)
- Sirolimus (Final May 2015, Draft Nov 2013) NTID
- Sitagliptin (Final Apr 2016, Draft Jul 2015)
- Sorafenib (Final May 2015, Draft Nov 2013)
- Sunitinib (Final May 2015, Draft Dec 2013)
- Tacrolimus (Final Apr 2016, Draft Oct 2015) NTID
- Tadalafil (Rev. 1 Jan 2018, Draft Jul 2017; Final May 2015, Draft Nov 2013)
- Telithromycin (Final May 2015, Draft Nov 2013)
- Ticagrelor (Final Apr 2016, Draft Oct 2015)
- Vandetanib (Final Feb 2017, Draft Aug 2016)
- Vemurafenib (Final Feb 2017, Draft Aug 2016)
- Vismodegib (Final Jul 2018, Draft Jan 2018)
- Voriconazole (Final May 2015, Draft Nov 2013)
- Vortioxetine (Final May 2018, Draft Dec 2016)
- Zonisamide (Final Apr 2016, Draft Jul 2015)
- Pharmacokinetics
- Pharmacokinetic Studies in Man: Oct 1988 (PDF39KiB)
- GL on the Evaluation of the PK of Medicinal Products in Patients with Decreased Renal Function: Dec 2015 (PDF181KiB),
Draft Feb 2014 (PDF195KiB), CP Jun 2012 (PDF66KiB), NfG Jun 2004 (PDF213KiB)
- Evaluation of the PK of Medicinal Products in Patients with Impaired Hepatic Function: Feb 2005 (PDF92KiB)
- CP on the Revision of the GL on the role of PK in the Development of Medicinal Products in the Paediatric Population: May 2017 (PDF109KiB)
- PK in the Development of Medicinal Products in the Paediatric Population: Jun 2006 (PDF115KiB)
- Reporting Results of Population PK Analyses: Jun 2007 (PDF68KiB)
- CP on qualification and reporting of PBPK modelling and analyses: Jun 2014 (PDF91KiB)
- GL on Strategies to Identify and Mitigate Risks for First-In Human and Early Clinical Trials with IMPs: Jul 2017 (PDF228KiB), Jul 2007 (PDF83KiB)
- RP: Use of Pharmacogenetics in the PK Evaluation of Medicinal Products: May 2007 (PDF61KiB)
- CP on the Development of a Guideline on the Use of Pharmacogenomic Methodologies in the PK Evaluation of Medicinal Products: Apr 2009 (PDF53KiB)
- Statistical Issues
- Biostatistical Methodology in Clinical Trials*: Oct 1993 ( PDF153KiB).
- GL on multiplicity issues in clinical trials: Draft Dec 2016 (PDF189KiB),
CP May 2012 (PDF66KiB), PtC Sep 2002 (PDF208KiB)
- GL on missing data in confirmatory clinical trials: Jul 2010 (PDF142KiB)
Draft Apr 2009 (PDF99KiB) Recommendation for the Revision of the PtC on Missing Data (CPMP/EWP/1776/99): Dec 2007 (PDF35KiB) PtC on Missing Data Nov 2001 (PDF38KiB)
- Biotechnological and Biological Products, Biosimilars
- Development Pharmaceutics for Biotechnological and Biological Products – Annex to NfG on Development Pharmaceutics: Oct 1999 (PDF36KiB)
- Clinical Investigation of the PK of Therapeutic Proteins: Jan 2007 (PDF98KiB)
Draft Jul 2005 (PDF101KiB)
- Similar Biological Medicinal Products: Oct 2014 (PDF121KiB), Overview of comments (PDF1.25MiB)
Draft Apr 2013 (PDF117KiB) CP Nov 2011 (PDF137KiB), Final Oct 2005 (PDF106KiB), Q&A on biosimilar medicines: Oct 2008 (PDF30KiB)
- Requirements for quality documentation concerning biological investigational medicinal products in clinical trials: Mar 2012 (PDF178KiB)
- EMA Procedural advice for users of the CP for similar biological medicinal products applications: Feb 2019 (PDF175KiB)
- GL on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (Rev. 1): Draft May 2012 (PDF128KiB)
- Biosimilars containing Biotechnology-Derived Proteins as Active Substance: Quality Issues: Feb 2006 (PDF137KiB)
- Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: Rev.1 Dec 2014 (PDF165KiB)
Draft Jun 2013 (PDF356KiB) CP Sep 2011 (PDF142KiB), Final Feb 2006 (PDF102KiB)
- Comparability of Biotechnology-Derived Medicinal Products after a change in the Manufacturing Process – Non-Clinical and Clinical Issues: Jul 2007 (PDF118KiB)
Draft Jan 2007 (PDF171KiB) CP Feb 2006 (PDF38KiB) Final Dec 2003 (PDF194KiB)
- Product specific biosimilar guidelines
- Recombinant Human Insulin and Insulin Analogues: Feb 2015 (PDF143KiB),
Draft Dec 2012 (PDF129KiB), CP Jul 2011 (PDF248KiB), Feb 2006 (PDF102KiB)
- Recombinant and human plasma-derived factor VIII: Rev. 2 Jul 2018 (PDF493KiB)
- Somatropin: Feb 2006 (PDF78KiB), Annex Jun 2018 (PDF252KiB)
- Recombinant Granulocyte-Colony Stimulating Factor: Rev. 1 Draft Jul 2018 (PDF150KiB), Final Feb 2006 (PDF89KiB),
CP Jul 2015 (PDF87KiB)
- Recombinant Erythropoietins: Rev. 1 Jun 2018 (PDF264KiB), Apr 2010 (PDF133KiB),
Draft Jul 2009 (PDF108KiB), CP Jul 2008 (PDF43KiB), Final Mar 2006 ( PDF45KiB)
- Low-molecular-weight-heparins: Final Nov 2016 (PDF129KiB),
Draft Jan 2013 (PDF167KiB), CP Jul 2011 (PDF252KiB), Draft Mar 2009 (PDF63KiB), Draft Apr 2008 (PDF55KiB), CP Jan 2007 (PDF72KiB)
- Interferon alpha: RP Jun 2009 (PDF97KiB),
Draft Oct 2007 (PDF102KiB), CP Apr 2006 (PDF72KiB)
- Interferon beta: Draft Jan 2012 (PDF155KiB),
CP Mar 2010 (PDF179KiB)
- Immunogenicity assessment of monoclonal antibodies: CP Mar 2009 (PDF39KiB)
- Monoclonal antibodies: May 2012 (PDF211KiB),
Draft Nov 2010 (PDF192KiB)
- Follicle stimulation hormone: Draft Nov 2011 (PDF159KiB),
CP Mar 2010 (PDF125KiB)
- Human normal immunoglobulin for intravenous administration (IVIg): Rev. 3 Jun 2018 (PDF198KiB)
- Miscellaneous
- Q&A: Positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP): Nov 2015 (PDF473KiB), Jun 2015 ( PDF507KiB), Jan 2015 ( PDF535KiB), Oct 2014 ( PDF494KiB), May 2014 ( PDF479KiB), Oct 2013 ( PDF452KiB), Feb 2013 ( PDF403KiB), Dec 2012 ( PDF300KiB), Sep 2012 ( PDF419KiB), Feb 2012 ( PDF282KiB), Jan 2011 ( PDF195KiB), Jul 2010 ( PDF182KiB), Jul 2009 ( PDF), Jun 2009 ( PDF94KiB), Jan 2009 ( PDF87KiB)
- Validation of Bioanalytical Methods: Jul 2011 (PDF159KiB), Overview of comments Jul 2011 (PDF2.64MiB),
Draft Nov 2009 (PDF135KiB) CP Dec 2008 (PDF52KiB)
- Validation of Analytical Procedures. Text and Terminology: Nov 1994; Methodology: Dec 1996 (PDF186KiB)
- NfG on Development Pharmaceutics: Jan 1998 (PDF58KiB)
- Scientific Advice & Protocol Assistance: Rev. 9, May 2017 (PDF280KiB)
- Tests on Samples of Biological Origin: Jul 1989 (PDF39KiB)
- Clinical Investigation of Chiral Active Substances: Apr 1994 (PDF52KiB)
- Topicals: Nov 1995 (PDF43KiB)
- GL on clinical development of fixed combination medicinal products: Mar 2017 (PDF134KiB),
Draft Apr 2015 (PDF164KiB), CP Feb 2013 (PDF163KiB), Final Feb 2009 (PDF92KiB), Draft Feb 2008 (PDF52KiB)
- Drug Interactions: CP Apr 2017 (PDF80KiB), Final Jun 2012 (PDF852KiB)
Draft Apr 2010 (PDF352KiB) CP Jul 2008 (PDF31KiB) Final Dec 1997 (PDF79KiB)
- Development Pharmaceutics: Jan 1998 (PDF58KiB)
Dry Powder Inhalers*: Jun 1998 ( PDF45KiB)
- PtC on the Requirements for Clinical Documentation for OIPs: Apr 2004 (PDF159KiB)
- Recommendation on the Need for Revision of PtC on the Requirements for Clinical Documentation for OIPs: Feb 2007 (PDF36KiB)
- CP on revision of the GL on the requirements for clinical documentation for OIPs including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and COPD: Feb 2017 (PDF94KiB), Final Jan 2009 (PDF271KiB),
Draft Oct 2007 (PDF176KiB), Appendix 1: Mar 2008 (PDF44KiB)
- GL on pharmaceutical development of medicines for paediatric use: Aug 2013 (PDF259KiB) Overview of Comments Aug 2013 (PDF741KiB)
Draft 2 Jan 2013 (PDF240KiB) Draft 1 May 2011 (PDF247KiB)
- Gender Considerations in the Conduct of Clinical Trials: Jan 2005 (PDF75KiB)
- Strategy paper: Acceptance of clinical trials conducted in third countries, for evaluation in MAAs: Dec 2008 (PDF31KiB)
- RP on ethical and GCP aspects of clinical trials of medicinal products for human use conducted outside of the EU/EEA and submitted in MAAs to the EU Regulatory Authorities: Apr 2012 (PDF293KiB)
- Inspections procedure – GCP: Set of documents, Sep 2007 – Mar 2017 (e.g., Triggers for Inspections PDF122KiB, Investigator Site PDF39KiB, Sponsor and/or CROs PDF36KiB, Phase I Units PDF31KiB, Bioanalytical part, PK and Statistical analyses of BE Trials PDF99KiB, …)
- Inspections – Q&A: Good clinical practice (GCP): 2020 (HTML208KiB)
- RP for laboratories that perform the analysis or evaluation of clinical trial samples: Feb 2012 (PDF167KiB)
- RP on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials: Jun 2010 (PDF127KiB)
- Heads of Medicines Agencies / Human Medicines
All pages refer to current documents (PDF).
- USA (FDA)
- Legislation (excerpts of the Code of Federal Regulations (CFR), Title 21)
- CDER’s Manual of Policies and Procedures
- Inspections of Clinical Facilities and Analytical Laboratories Conducting BE Studies Submitted in ANDAs: Sep 2012 ( PDF49KiB)
- Review of Investigational New Drug Applications (Bio-INDs): Oct 2016 (PDF126KiB)
- Review of BE Studies with Clinical Endpoints in ANDAs: Jun 2017 (PDF71KiB)
- Filing Review of ANDAs: Sep 2017 (PDF521KiB)
- Bioavailability / Bioequivalence
- The ‘Orange Book’: 41th Edition, 2021 (PDF10.2MiB as of Dec 31, 2020, Cumulative supplement [published monthly], Electronic ‘Orange Book’: Current version [including online search])
- BE Studies with PK Endpoints for Drugs Submitted Under an ANDA: Draft Dec 2013 (PDF128KiB)
- BE and BA Studies Submitted Under an NDA or IND: Draft Feb 2019 (PDF254KiB)
Draft Mar 2014 (PDF805KiB)
- BA/BE—General Considerations: Rev. 1, Mar 2003 ( PDF268KiB)
- Assessing the Effects of Food on Drugs in INDs and NDAs — Clinical Pharmacology Considerations: Feb 2019 (PDF153KiB)
- Food-Effect BA / Fed BE: Dec 2002 (PDF166KiB)
- Statistical Approaches Establishing BE: Jan 2001 (PDF130KiB)
Statistical Procedures for BE Studies using a Standard Two-Treatment Crossover Design: Jul 1992 ( PDF1.4MiB)
- Dissolution Testing of IR Solid Oral Dosage Forms: Aug 1997 (PDF130KiB)
- Dissolution Testing and Specification Criteria for IR Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances: Aug 2018 (PDF103KiB)
Draft Aug 2015 ( PDF87KiB)
- Biowaivers / BCS: Dec 2017 (PDF161KiB)
Draft May 2015 ( PDF141KiB), Aug 2000 ( PDF54KiB)
Oral extended (controlled) release dosage forms in vivo BE and in vitro dissolution testing: Aug 1996 ( PDF34KiB)
- ER / in vitro/in vivo Correlations: Sep 1997 (PDF170KiB)
- BA/BE for Nasal Aerosols / Sprays for Local Action: Draft Apr 2003 (PDF519KiB; Statistical Information PDF185KiB)
- SUPAC [IR]: Nov 1995 (PDF60KiB, 1997 Questions and Answers HTML21KiB)
- SUPAC [MR]: Sep 1997 (PDF215KiB)
- SUPAC [SS]: May 1997 (PDF118KiB)
- BE Recommendations for Specific Products: Jun 2010 (PDF80KiB)
Product-Specific Guidances for Generic Drug Development (search page)
- Critical Path Opportunities for Generic Drugs: May 2007 ( HTML73KiB)
- Detailed information regarding labeling, scale-up, packaging, minor/major amendment criteria and BE requirements: Aug 1993 (PDF908KiB)
- Variations in Drug Products that May Be Included in a Single ANDA: Dec 1998 (PDF107KiB)
- Handling/Retention of BA/BE Samples: May 2004 (PDF166KiB)
- ANDA Checklist for Completeness and Acceptability: Mar 2011 ( PDF140KiB)
- Model BE Data Summary Tables: Feb 2017 (PDF185KiB, DOC634KiB)
- Submission of Summary BE Data for ANDAs: May 2011 ( PDF137KiB)
- ANDA Submissions — Content and Format of ANDAs: Draft Jun 2014 (PDF214KiB)
- ANDA Submissions — Refuse-to-Receive Standards: Rev. 2 Dec 2016 (PDF200KiB),
Rev. 1 May 2015 ( PDF206KiB), Final Sep 2014 ( PDF229KiB), Draft Oct 2013 ( PDF476KiB)
- Self-Identification of Generic Drug Facilities, Sites, and Organizations: Sep 2016 (PDF268KiB)
Draft Aug 2012 ( PDF209KiB), FAQs (HTML12KiB)
- Biosimilars
- Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product: Dec 2016 (PDF150KiB),
Draft May 2014 ( PDF142KiB)
- Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Apr 2015 (PDF169KiB),
Draft Feb 2012 ( PDF576KiB)
- Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product: Apr 2015 (PDF144KiB),
Draft Feb 2012 ( PDF432KiB)
- Biosimilars: Q&A Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009: Rev.2 Dec 2018 ( PDF680KiB),
Rev.1 May 2015 ( PDF104KiB), Draft Feb 2012 ( PDF177KiB)
- Miscellaneous
- Assessing Adhesion with Transdermal Delivery Systems and Topical Patches for ANDAs: Draft Oct 2018 (PDF187KiB),
Draft Jun 2016 ( PDF189KiB)
- Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules: Jun 2015 (PDF89KiB),
Draft Dec 2013 ( PDF75KiB)
- Size of Beads in Drug Products Labeled for Sprinkle: May 2012 (PDF148KiB)
- Adaptive Designs for Clinical Trials of Drugs and Biologics: Sep 2018 (PDF623KiB)
- Bioanalytical Method Validation: May 2018 (PDF341KiB),
Rev. 1 Sep 2013 ( PDF526KiB), Final May 2001 ( PDF63KiB)
- Reviewer Guidance—Validation of Chromatographic Methods: Nov 1994 (PDF703KiB)
- Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products: May 1998 (PDF129KiB)
- PK in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing and Labeling: Draft Mar 2010 (PDF318KiB), May 1998 (PDF128KiB)
- General Considerations for Pediatric PK Studies for Drugs and Biological Products: Draft Nov 1998 ( PDF37KiB)
- PK in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling: May 2003 (PDF222KiB)
- Guidance for Industry Providing Regulatory Submissions in Electronic Format—Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications: Rev. 2, Jun 2008 ( PDF133KiB)
- Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers: Jul 2005 (PDF702KiB)
- Current GMP for Phase 1 Investigational Drugs: Jul 2008 (PDF132KiB)
- Population PK: Feb 1999 (PDF135KiB)
- Safety Testing of Drug Metabolites: Rev.1 Nov 2016 PDF185KiB, Feb 2008 ( PDF86KiB)
- In Vitro Drug Interaction Studies—Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions: Jan 2020 ( PDF458KiB),
Draft Oct 2017 ( PDF396KiB)
- Clinical Drug Interaction Studies—Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions: Jan 2020 ( PDF251KiB),
Draft Oct 2017 (PDF224KiB), Draft Feb 2012 ( PDF827KiB)
- Exposure-Response Relationships—Study Design, Data Analysis, and Regulatory Applications: Apr 2003 (PDF221KiB)
- Guidance for Sponsors, Clinical Investigators, and IRBs. Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials: Oct 2008 (PDF75KiB)
- Investigator Responsibilities—Protecting the Rights, Safety, and Welfare of Study Subjects: Oct 2009 (PDF163KiB)
- Guidance for IRBs, Clinical Investigators, and Sponsors: 1998—2019 (HTML10KiB)
- Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs; Frequently Asked Questions–Statement of Investigator (Form FDA 1572): May 2010 (PDF105KiB)
- Safety Reporting Requirements for INDs and BA/BE Studies: Dec 2012 (PDF227KiB),
Draft Sep 2010 ( PDF688KiB)
- International Compilation of Human Research Standards: 2019 (PDF2.93MiB)
- General Principles of Software Validation; Final Guidance for Industry and FDA Staff: Jan 2002 (PDF161KiB)
- Part 11, Electronic Records; Electronic Signatures — Scope and Application: Aug 2003 ( PDF215KiB)
- Computerized Systems Used in Clinical Investigations: May 2007 (PDF53KiB)
- GLP (Non-Clinical Laboratories)
- Compliance Program Guidance Manual: Feb 2001 ( PDF117KiB)
Final Rule: Dec 1978 ( PDF6.4MiB)
Proposed Rule: Oct 1984 ( PDF1.7MiB)
- Final Rule: Sep 1987 ( PDF3.0MiB)
- Questions and Answers: Jun 1981, Dec 1999, Jul 2007 (PDF52KiB)
- In Vivo Bioavailability/Bioequivalence Studies: May 2018 ( PDF695KiB)
- Sponsors, Contract Research Organizations and Monitors: Apr 2017 (PDF314KiB)
- Clinical Investigators: Dec 2008 ( PDF240KiB)
Computerized Systems Used In Clinical Trials: Apr 1999 ( PDF46KiB); for the current version (May 2007) see CDER’s document linked in the previous section.
- GL for the Monitoring of Clinical Investigations: Jan 1988 ( HTML9KiB)
- Institutional Review Boards: Sep 2018 ( PDF371KiB)
- Canada (HPFB/TPD)
- Conduct and Analysis of Comparative BA Studies: Jun 2018 (PDF652KiB, HTML42KiB)
Final May 2012 ( PDF181KiB) Draft Nov 2009 ( PDF1.05MiB) Final 1992 ( PDF151KiB)
- Comparative BA Standards: Formulations used for Systemic Effects: Jun 2018 (PDF680KiB, HTML17KiB)
Final May 2012 ( PDF61KiB)
- Proposed Policy on BE Standards for HVDPs: Apr 2016 (HTML26KiB)
Jun 2015 (HTML27KiB)
- BCS Based Biowaiver: May 2014 (PDF118KiB, HTML20KiB),
Draft Aug 2012 (HTML13KiB)
- Stereochemical Issues in Chiral Drug Development: Feb 2000 (PDF56KiB)
- Information and Submission Requirements for Subsequent Entry Biologics (SEBs): Revised Nov 2016 (PDF171KiB, HTML27KiB)
- Inclusion of Women in Clinical Trials: May 2013 (HTML28KiB)
- Drug Interactions: Sep 2000 (PDF69KiB, HTML93KiB)
- CTAs for Comparative BA Studies: Dec 2015 (HTML13KiB)
- Records Related to Clinical Trials: May 2006 (PDF138KiB, HTML23KiB)
- Preparation of Comparative BA Information for Drug Submissions in the CTD Format: Draft May 2004 (PDF91KiB, HTML28KiB)
- Japan (PMDA)
- Clinical Pharmacokinetic Studies of Pharmaceuticals: Jun 2001 (PDF502KiB)
- BE Studies for Generic Products: Feb 2012 (PDF177KiB, PDF482KiB ja, Q&A Document PDF309KiB, PDF590KiB ja; Nov 2006:
GL PDF175KiB, PDF480KiB ja, Q&A Document PDF407KiB ja; Dec 1997: GL PDF60KiB, HTML109KiB)
- Generic Products for Different Strengths of Oral Solid Dosage Forms: Feb 2012 (PDF120KiB, PDF377KiB ja, Q&A Document PDF161KiB, PDF421KiB ja; Nov 2006:
GL PDF78KiB, PDF235KiB ja; Q&A Document PDF471KiB ja: Feb 2000: GL PDF33KiB, HTML19KiB)
- Formulation Changes of Oral Solid Dosage Forms: Feb 2012 (PDF121KiB, PDF374KiB ja, Q&A Document PDF161KiB, PDF471KiB ja; Nov 2006:
GL PDF107KiB, PDF251KiB ja, Q&A Document PDF471KiB ja; Feb 2000: GL PDF34KiB)
- Different Oral Solid Dosage Forms: Feb 2012 (PDF18KiB, PDF131KiB ja, Q&A Document PDF42KiB, PDF145KiB ja)
- Generic Products for Ethical Combination Drug Products: Feb 2012 (Q&A Document PDF16KiB, PDF101KiB ja)
- Different Strengths of Ethical Combination Drug Products and Formulation Changes of Ethical Combination Drug Products: Feb 2012 (Q&A Document PDF56KiB, PDF158KiB ja)
- Generic Products for Topical Use: Nov 2006 (PDF ja, Q&A Document PDF ja; Nov 2003:
GL PDF68KiB)
- Adding Dosage Form for Topical Use: Nov 2006 (PDF236KiB ja, Q&A Document PDF43KiB ja)
- Oral Prolonged Release Dosage Forms: Mar 1988 (PDF53KiB)
- GL on Bioanalytical Method Validation in Pharmaceutical Development (ligand binding assays incl. Q&A): final May 2014 (PDF899KiB)
- GL on Bioanalytical Method Validation in Pharmaceutical Development (chromatographic methods incl. Q&A): final Sep 2013 (PDF343KiB PDF535KiB ja)
- GL on Bioanalytical Method Validation in Pharmaceutical Development: draft Apr 2013 (PDF204KiB PDF251KiB ja)
- South African HPRA
- Biostudies: Jul 2015 (PDF279KiB)
- Dissolution: Jul 2015 (PDF279KiB)
- Biosimilars: Draft Aug 2014 (PDF589KiB)
- Pharmaceutical and Analytical (e)CTD: Aug 2014 (PDF1.46MiB)
- Substitution of Medicines: Apr 2010 (PDF99KiB)
- Australia (TGA)
- BA and BE: Jun 2011 (PDF237KiB)
- Summary of a BA or BE Study: Dec 2002 (PDF107KiB)
- Australian Regulatory GLs for Prescription Medicines, Appendix 15: Biopharmaceutic Studies: Jun 2004 (PDF178KiB)
- Clinical GLs of the European Union adopted in Australia: current (HTML)
- Evaluation of biosimilars: Jul 2013 (HTML)
- New Zealand (Medsafe)
- Guidance notes for applicants for consent to distribute new and changed medicines and related products (including BA/BE): Final, Oct 2001 (DOC5.0MiB)
- Biostudy Reference Products: Jul 2006 (HTML5KiB)
- India (CDSCO)
- New Drugs and Clinical Trials Rules: Mar 2019 (PDF2.40MiB)
- Bioavailability / Bioequivalence: Draft Mar 2005 ( PDF106KiB),
Draft Mar 2003 ( HTML0.99MiB)
- Requirements and GLs for Permission to Import and / or Manufacture of New Drugs for Sale or to Undertake Clinical Trials: Schedule Y – Amended Version, Jun 2005 (PDF8.7MiB, HTML681KiB)
- Guidance document for approval of BA/BE NOC for export purpose as per Schedule Y & test licence in form 11 of drugs and cosmetics rules, 1945: Draft Jan 2018 (PDF934KiB), Jan 2014 (PDF283KiB)
- GCP: 2005 (HTML834KiB)
- GCP Inspection Checklist: Aug 2016 (PDF261KiB)
- Guidance on Approval of Clinical Trials & New Drugs: Draft Jul 2011 (PDF643KiB)
- Submission of Clinical Trial Application for Evaluating Safety and Efficacy: v1.1 Dec 2008 (PDF704KiB)
- CRO registration: Draft Jan 2011 (PDF565KiB)
- Inspection of Clinical Trial: Draft Jul 2012 (PDF658KiB)
- Amended Checklist for Test Licence Applications effective from 15 June 2011 (PDF69KiB)
- Clarification & Amendments in guidance for industry with respect to Post Approval Changes in Biologicals Products: Aug 2010 (PDF147KiB)
- Registration of Ethics Committee: Draft Jul 2012 (PDF1.56MiB)
- Audio-Visual Recording of Informed Consent Process in Clinical Trial: Draft Jan 2014 (PDF433KiB)
- Ethical GLs for Biomedical Research on Human Participants (published by the Indian Council of Medical Research): Oct 2017 (PDF8.9MiB), Oct 2006 (PDF3.1MiB)
- Bangladesh (DGDA)
- GL on Regulation and Licensing of Biological Products: May 2018 (PDF6.64MiB) Note: WHO TRS 858 Annex 1 of 1995 is applicable.
- Requirements for CRO/Clinical Trial Centre: Jan 2018 (PDF1.28MiB)
- GLs for GCP for Trials on Pharmaceutical Products: Nov 2011 (PDF329KiB)
- Guidance on Clinical Trial Inspection: Jan 2011 (PDF85KiB)
- Guidance for Industry on Submission of Clinical Trial Application for Evaluating Safety and Efficacy: Jan 2010 (PDF1.17MiB)
- PAHO
- GCP – Document of the Americas: 2005 (PDF306KiB)
- Framework for implementation of equivalence requirements for pharmaceutical products: Nov 2008 (PDF326KiB)
- Science Based Criteria for BE in vivo and in vitro, Bio-Waivers and Strategic Framework for Implementation: Draft >2001? (PDF971KiB)
- BA / BE / Biowaivers: Final Draft Aug 2004 (PDF868KiB)
- Brazil (ANVISA)
- Implementation of Relative BA and BE Studies: Apr 2006 (PDF94KiB pt),
Nov 2004 (PDF pt), May 2003 (PDF pt)
- Pharmaceutical Equivalence / Dissolution: Aug 2010 (PDF101KiB pt)
- Exemption and Substitution of BE Studies (Biowaiver): Aug 2011 (PDF87KiB)
- List of candidate drugs for BCS based biowaivers: Sep 2016 (PDF pt),
Aug 2014 (PDF pt), Mar 2013 (PDF pt), Aug 2011 (PDF pt)
- Bioanalytical Method Validation: May 2012 (PDF215KiB pt)
- National Registry of Volunteers in BE Studies: Jun 2008 (PDF pt)
- Statistics for BA/BE Studies: May 2003 (HTML49KiB pt)
- Protocol of BE Studies: May 2003 (HTML32KiB en, HTML16KiB pt,
Mar 2002 HTML28KiB pt)
- Report of BE Studies: May 2003 (HTML63KiB en, HTML55KiB pt)
- List of Reference Products: Current (PDF265KiB pt)
- Rules / Technical Regulations for CROs: May 2003 (HTML720KiB en, HTML586KiB pt)
- Annex I: Certification for BA/BE Centers: (Application Form DOC395KiB,
DOC148KiB; Renewal Form DOC370KiB, RTF365KiB)
- Annex II: GLs for Inspection at Centers of BA/BE of Medicines (
DOC pt)
- Annex III: Certificate of Good Practices of BA/BE of Medicines (GIF1KiB pt)
- Annex IV: Form for Outsourcing of Phase for Assays of BA/BE of Medicines (
DOC pt)
- Annex V: Form for Monthly Report of Assays of BA/BE of Medicines (
DOC pt)
- Guidance for Pharmaceutical Equivalence and Bioequivalence of Nasal Sprays and Aerosols: Oct 2009 (PDF pt)
- Volume 1 (clinics, analytics, statistics): 2002 (ZIP/PDF6.1MiB en, ZIP/PDF4.3MiB pt)
- Volume 2 (micropipets, water for analysis, instrumentation): 2002 (ZIP/PDF6.2MiB en, ZIP/PDF4.7MiB pt)
- Mexico
- Argentina
- Regulatory GL for GCP in Clinical Pharmacology Studies: Nov 2011 (PDF222KiB en, PDF1.01MiB es)
- GCP GL for studies in human subjects: Nov 2007 (PDF201KiB es)
GCP in Clinical Studies: 1997, amended 2005 (PDF143KiB es)
- BA/BE: Final Sep 2006, amended Mar 2007 (PDF1.8MiB es,
1999 PDF389KiB es)
- BCS based Biowaivers for oral solid IR dosage forms: Feb 2009 (PDF97KiB es)
- Post approval changes: Feb 2009 (PDF154KiB es)
- Bioanalytical Method Validation: Jul 2013 (PDF1.15MiB es),
Sep 2005 (PDF130KiB es)
- Colombia
- BA/BE: Apr 2016 (PDF1.46MiB es)
- Saudia Arabia
- BE:UD v3.0 Oct 2021 (PDF1.56MiB), v2.4 Mar 2016 (PDF1.09MiB)
- Biowaiver: Jul 2013 (PDF881KiB)
- Variation Requirements: Feb 2017 (PDF1.12MiB)
- GL on Pharmaceutical Equivalence Requirements: Sep 2010 (PDF107KiB)
- Regulations and Requirements for Conducting Clinical Trials on Drugs: Jul 2015 (PDF843KiB)
- GLs for IND requirements: Sep 2010 (PDF315KiB)
- GLP: Draft Feb 2006? (PDF269KiB)
- Drug Master File Requirements for the Registration of Biosimilars: Dec 2010 (PDF154KiB)
- GLs on Biosimilars: Dec 2010 (PDF1.2MiB)
- Jordan
- Law of clinical studies: 2003 (DOC55KiB ar),
2001 (DOC59KiB en)
- Oman
- Guidance on eCTD Submissions: Mar 2018 (PDF577KiB)
- GCC Guidelines for Variation Requirements: Feb 2017 (PDF919KiB)
- BCS Biowaiver’s drug Application Form: ≥Jun 2018 (PDF1.97MiB)
- Egypt
- GL for Registration of Biosimilar Products: Nov 2013 (PDF7811KiB)
- BE Studies GL: Feb 2017 (PDF2.0MiB)
Jan 2010 (PDF1.0MiB)
- ASEAN States (ACCSQ)
- ASEAN GL for the Conduct of BA and BE Studies: Final Mar 2015 (PDF419KiB)
- BE Studies Reporting Format: Feb 2008 (PDF37KiB)
- BE, Q&A: Version 5, Jul 2012 (PDF65KiB); Version 4, Jun 2011 (PDF69KiB); Version 3, Jul 2010 (PDF11KiB); Version 2, May 2009 (PDF67KiB); Version 1, Jul 2008 (PDF16KiB)
- Malaysia (BPFK)
- Guidance on BCS – Based Biowaiver: Jan 2013 (PDF150KiB)
- GCP: Second Edition, Jan 2004 (PDF646KiB)
- GLP: Jun 2009 (OECD’s adopted; see PDF368KiB)
- Guidance Document and GLs for Registration of Biosimilars: Aug 2008 (PDF166KiB)
- Thailand (FDA)
- Guidance for Preparation of the In vivo BE Study Report: 2010 (PDF1.4MiB)
- BA/BE: Mar 2015 (PDF606KiB)
- Singapore (HSA, 卫生科学局)
- Drug Registration Information and Guidelines
- Announcement – Revision to Guidance on Medicinal Product Registration in Singapore: Mar 2012 (PDF99KiB)
- Guidance on Medicinal Product Registration in Singapore: Apr 2011 (complete document: PDF6.0MiB, main document: PDF2.6MiB)
- Product Interchangeability and Biowaiver Request for chemical Generic Drug Applications: Feb 2007 (Appendix 15 PDF47KiB)
- Guidance on Registration of Similar Biological Products: Aug 2009 (PDF126KiB)
- ASEAN Common Technical Requirements (ACTR)
- BA / BE: Final Draft Jul 2004 (PDF127KiB)
- Validation of Analytical Procedures: Draft Jan 2007 (PDF123KiB)
- ASEAN GL on Analytical Validation – Q&A: Version 1, Jun 2012 (PDF145KiB)
- Indonesia
- Guidelines
- GL on BE: 2004 (PDF536KiB id)
- Indonesian GL for GCP: Dec 2006 (PDF9.16MiB)
- (South) Korea
- Guidance Document for BE Study: Dec 2008 (PDF604KiB)
Minimum Requirements for BE Test: Dec 2005 (PDF493KiB)
- Taiwan
- Regulations 台灣藥物法規資訊網 zh
- GLs for Bioavailability & Bioequivalence (BA/BE) Studies: Apr 2009 (PDF199KiB)
BA/BE: Dec 2006 (PDF171KiB zh, HTML47KiB zh)
- GL on the Examination and Registration of Drugs — GL on Biosimilar products: Nov 2008 (PDF492KiB)
- GCP: Jan 2005 (PDF365KiB, PDF248KiB zh, HTML230KiB zh)
- Pediatric PK: Jul 2002 (PDF195KiB zh, HTML158KiB zh)
- Ethnic Factors in the Acceptability of Foreign Clinical Data: May 2002 (PDF323KiB zh)
- GLP: Mar 2006 (PDF200KiB zh, HTML197KiB zh)
- Nonclinical Pharmacology/Toxicology: Jun 2000 (PDF1.0MiB zh, HTML1.9MiB zh)
- Analytical Method Validation: Jan 2000 (PDF223KiB zh, HTML172KiB zh)
- China
- Drug Administration Law: Dec 2001 (HTML68KiB)
- Regulations for Implementation of the Drug Administration Law: Sep 2002 (HTML67KiB)
- Good Clinical Practice: Aug 2003 (HTML46KiB zh)
- Statistical GLs for Clinical Trials of Drugs and Biologics: Mar 2005 (PDF324KiB zh)
- Pharmacokinetics: 2005 (PDF300KiB zh)
- Chinese Pharmacopeia, Appendix 9011: 2015 ( PDF555KiB zh)
- Bioequivalence: Mar 2016 (DOCX55KiB zh)
2005 (PDF328KiB zh)
- Hong Kong; GCP for Proprietary Chinese Medicines: Feb 2004 (PDF242KiB en, PDF669KiB zh)
- Russian Federation
- Drugs BE Evaluation: 2008 (PDF193KiB)
- Methodological recommendations for drug manufacturers on in vitro equivalence test for generic drug products according to biowaiver procedure: Draft 2010 (PDF221KiB)
- Rules for GCP: Apr 2016 (DOCX47KiB)
- Eurasian Economic Union
- Agreement Medicinal Products within the EEU: Dec 2014 (PDF249KiB, PDF7.21MiB ru)
- Rules for GCP within the EEU: Nov 2016 (PDF1.72MiB ru)
- Rules for marketing authorization within the EEU: Nov 2016 (PDF4.37MiB, PDF5.69MiB ru)
- Regulations conducting BE studies within the framework of the EEU: Nov 2016 (PDF1.46MiB ru),
Dec 2015 (PDF1.58MiB ru)
- GL on quality for oral MR drugs: Jan 2018 (PDF345KiB)
- GL for oral MR products: Sep 2016 (PDF467KiB ru)
- Switzerland
- Authorisation of human medicines with known active pharmaceutical ingredients: Aug 2014 (PDF684KiB)
- Authorisation of human medicines with new active pharmaceutical ingredients and major variations: Sep 2014 (PDF496KiB)
- Authorisation of human medicinal products already authorised in foreign countries: Nov 2015 (PDF463KiB) Q&A regarding the application of the Administrative Ordinance (Art. 13, Therapeutic Products Act, HTML10KiB)
- Authorisation of similar biological medicinal products (Biosimilars): Aug 2014 (PDF402KiB)
Federal Office of Public Health – AGIT
Guidelines on computerized systems
- GLs for the archiving of Electronic Raw Data in a GLP Environment: May 2003 (PDF124KiB)
- GLs for the management of electronic SOPs in GLP: Sep 2006 (PDF134KiB)
- GLs for the acquisition and processing of electronic raw data in a GLP environment: Sep 2006 (PDF166KiB)
- GLs for the validation of computerised Systems in a GLP Environment: Dec 2007 (PDF344KiB)
- GLs for the Change Management and Risk Assessment of validated computerised Systems in a GLP Environment: Dec 2012 (PDF64KiB)
- GLs for the Development and Validation of Spreadsheets: Aug 2011 (PDF318KiB)
- Turkey
- Good Clinical Practice Guide: Nov 2015 (PDF659KiB tr)
- Good Laboratory Practice Principles: Jun 2002 (HTML55KiB tr)
- Licensing Regulation for Pharmaceutical Products: 2003 (PDF147KiB)
- Submission of BA/BE Dossiers: Jan 2006 ( PDF287KiB)
- Regulation on Assessment of BA and BE of Pharmaceutical Preparations: 1994? (HTML279KiB tr)
- Israel
- GLs for Clinical Trials in Human Subjects: Jan 2006 (PDF888KiB he, PDF204KiB en)
- SOP for Performing BE in Human Subjects: Sep 2002 (DOC132KiB he)
- Requirments for Registration of a Generic Product: Sep 2002 (DOC167KiB he)
- East African Community
- Compendium of Medicines Evaluation and Registration for Medicine Regulation Harmonization in the East African Community: Sep 2014 (PDF1.35MiB)
- Zimbabwe
- GLs on Good Clinical Trial Practice: 2012 (PDF661KiB)
- GL on Interchangeability: 2009 (PDF379KiB)
- BE application form: 2009 (PDF403KiB)
- GL on Biowaivers: Aug 2009 (PDF491KiB)
- List of substances for BCS based Biowaivers: Jun 2009 (PDF132KiB)
- Biowaiver application form: Aug 2009 (PDF236KiB)
- Biowaver application form for additional strengths: Aug 2009 (PDF242KiB)
- Uganda
- GLs on the Registration of Pharmaceuticals for Human use: Jul 2006 (PDF154KiB)
- Variations: Oct 2009 (PDF1.5MiB)
- OECD
OECD Environmental Health and Safety Publications, Series on Principles of Good Laboratory Practice and Compliance Monitoring (en, fr, de, es)
- OECD Principles of Good Laboratory Practice: Apr 1999 (PDF).
- Revised Guides For Compliance Monitoring Procedures for Good Laboratory Practice: Jun 1995 (PDF).
- Revised Guidance for the Conduct of Laboratory Inspections and Study Audits: Jun 1995 (PDF).
- Quality Assurance and GLP: Dec 1999 (PDF), FAQ (HTML).
- Compliance of Laboratory Suppliers with GLP Principles: Sep 2000 (PDF).
- The Application of the GLP Principles to Field Studies: Sep 2000 (PDF) – not applicable for PK/BA/BE/PK, just for completeness.
- The Application of the GLP Principles to Short Term Studies: Dec 1999 (PDF).
- The Role and Responsibility of the Study Director in GLP Studies: Oct 1999 (PDF).
- Guidance for the Preparation of GLP Inspection Reports: Oct 1999 (PDF).
- The Application of the Principles of GLP to Computerised Systems: Oct 1995 (PDF).
- The Role and Responsibilities of the Sponsor in the Application of the Principles of GLP: Mar 1998 (PDF).
- Requesting and Carrying Out Inspections and Study Audits in Another Country: Sep 2000 (PDF).
- The Application of the OECD Principles of GLP to the Organisation and Management of Multi-Site Studies: Jun 2002 (PDF).
- The Application of the Principles of GLP to in vitro Studies: Nov 2004 (PDF).
- Establishment and Control of Archives that Operate in Compliance with the Principles of GLP: Jun 2007 (PDF).
- PIC/S
- Good Practices for Computerized Systems in Regulated “GXP” Environments: Version 3, Sep 2007 (PDF443KiB)
- EDQM
- Validation of Analytical Procedures: Feb 2014 (PDF193KiB)
- Uncertainty of Measurements
- Part I (compliance testing): Dec 2007 (PDF703KiB)
- Part II (other than compliance testing): Dec 2007 (PDF1.0MiB)
- Qualification of Equipment (core document): Jul 2011 (PDF291KiB)
- Annex 1: Qualification of HPLC Equipment: Jul 2011 (PDF366KiB)
- Annex 2: Qualification of GC Equipment: Oct 2006 (PDF897KiB)
Abbreviations |
ACCSQ | Consultative Committee for Standards and Quality (→ ASEAN) |
AGIT | Arbeitsgruppe Informationstechnologie (Working Group on Information Technology, Switzerland) |
ANDA | Abbreviated New Drug Application (→ FDA) |
ANMAT | Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (National Administration for Medicines, Food and Medical Technology, Argentina) |
ANVISA | Agência Nacional de Vigilância Sanitária (National Agency for Sanitary Monitoring, Brazil) |
API | Active Pharmaceutical Ingredient |
ASEAN | Association of Southeast Asian Nations |
BA | Bioavailability |
BCS | Biopharmaceutics Classification System |
BE | Bioequivalence |
BPFK | Biro Pengawalan Farmaseutikal Kebangsaan (National Pharmaceutical Control Bureau, Malaysia) |
CDE | Center For Drug Evaluation (Taiwan) |
CDER | Center for Drug Evaluation and Research (of the → FDA) |
CDSCO | Central Drugs Standard Control Organization (India) |
CHMP | Committee for Medicinal Products for Human Use (of the → EMA) |
CFDA | China Food & Drug Administration |
CP | Centralised Procedure | Concept Paper (of the → EMA) |
CRO | Contract Research Organization |
CTA | Clinical Trial Application |
CTD | Common Technical Document (according to → ICH) |
DCD | Drug Control Division (Thailand) |
DCP | Decentralised Procedure (in the → EU) |
DGDA | Directorate General of Drug Administration (Bangladesh) |
DOC | Micro$oft’s Word Format |
DKMA | Danish Medicines Agency |
E | Efficacy (Topic of → ICH) |
eCTD | Electronic Common Technical Document (→ CTD) |
EDA | Egyptian Drug Authority |
EDQM | European Directorate for the Quality of Medicines & HealthCare |
EEA | European Economic Area |
EMA | European Medicines Agency (formerly European Medicines Evaluation Agency – EMEA) |
ER | Extended Release |
EU | European Union |
EWP | Efficacy Working Party (of the → EMA) |
FDA | Food and Drug Administration (United States) |
GCP | Good Clinical Practice(s) |
GLP | Good Laboratory Practice(s) |
GL | Guideline |
GIF | Graphics Interchange Format |
GMP | Good Manufacturing Practice(s) |
HPFB | Health Products and Food Branch (of Health Canada) |
HSA | Health Sciences Authority (Singapore) |
HVD | Highly Variable Drug |
HVDP | Highly Variable Drug Product |
ICH | International Council for Harmonisation |
IMP | Investigational Medicinal Product |
IND | Investigational New Drug |
INVIMA | Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia) |
IR | Immediate Release |
IRB | Institutional Review Board |
JPEG | Joint Photographic Experts Group (graphics format) |
JFDA | Jordan Food and Drug Administration |
KiB | Kilobyte = 1,024 Bytes (filesize) |
KFDA | (South) Korea Food & Drug Administration |
MA | Marketing Authorisation (in the → EU) |
MB | Megabyte = 1,024KB = 1,048,576 Bytes (filesize) |
MCC | Medicines Control Council; since 2017 SAHPRA (South African Health Products Regulatory Authority) |
MoH | Ministry of Health |
MR | Modified Release |
MRP | Mutual Recognition Procedure (in the → EU) |
NDA | National Drug Authority (Uganda) |
NfG | Note for Guidance (of the → EMA) |
NIHS | National Institute for Health Sciences (Japan) |
NIMP | Non Investigational Medicinal Product |
OECD | Organisation for Economic Co-operation and Development |
OGD | Office of Generic Drugs (of the → FDA) |
PAHO | Pan American Health Organization |
PDF | Adobe’s Portable Document Format |
PIC/S | Pharmaceutical Inspection Co-operation Scheme |
PK | Pharmacokinetics |
PtC | Points to Consider (of the → EMA) |
Q | Quality (Topic of → ICH) |
Q&A | Questions and Answers |
RP | Reflection Paper (of the → EMA) |
RTF | Rich Text Format |
SAHPRA | South African Health Products Regulatory Authority |
SFDA | Saudi Food & Drug Authority (Saudia Arabia) |
SOPitis | Inflammation of a CRO in order to comply with written instructions rather than following common sense |
SS | Semisolid |
SUPAC | Scale-Up and Post-Approval Changes (according to → FDA) |
TGA | Therapeutic Goods Administration (Australia) |
TIFF | Tagged Image File Format |
TİTCK | Türkiye İlaç ve Tıbbi Cihaz Kurumu (Turkish Medicines and Medical Devices Agency) |
TPD | Therapeutic Products Directorate (of → HPFB) |
WHO | World Health Organization |
ZIP | Compressed file (format) |